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ABSTRACT: Epidemiological studies of the association between drug use and involvement in road traffi c crashes 
(RTCs) published from January 1998 to February 2015 have been reviewed. Cohort and population studies compared 
RTC involvement among drug users and non–drug users, case-control studies compared drug use among RTC-
involved and non–RTC-involved drivers, and responsibility studies and case-crossover studies were performed 
for RTC-involved drivers. Diffi culties associated with the types of studies are discussed with a special focus on 
case-control studies. Statistically signifi cant associations between drug use and RTC involvement were found for 
benzodiazepines and z-hypnotics in 25 out of 28 studies, for cannabis in 23 out of 36 studies, for opioids in 17 out 
of 25 studies, for amphetamines in 8 out of 10 studies, for cocaine in 5 out of 9 studies, and for antidepressants in 
9 out of 13 studies. It was a general trend among studies that did not report signifi cant associations between the 
use of these drugs and increased RTC risk that they often had either poor statistical power or poor study design 
compared to studies that found an association. Simultaneous use of two or more psychoactive drugs was associated 
with higher RTC risk. Studies on the combination of alcohol and drugs have not been reviewed in this article even 
though this combination is known to be associated with the highest RTC risk.
 
KEYWORDS: Amphetamines, antidepressants, benzodiazepines, cannabis, cocaine, drugged driving, DUID, 
epidemiology, hypnotics, opioids, road traffi c crashes (RTCs).
INTRODUCTION
 A review article on the effect of drug use on road traffi c 
safety was published in this journal in 2000 [90]. The 
article included experimental and epidemiological studies 
published before 1998 for the following drug groups: 
benzodiazepines and related drugs, cannabis, opioids, 
amphetamine and related drugs, antihistamines, and 
antidepressants. Many investigations have been performed 
since then. In this article, epidemiological studies on drugs 
and traffi c safety published after 1998 are reviewed. An 
update of experimental studies will be published in a 
forthcoming issue of this journal together with a summary 
of the combined knowledge from epidemiological and 
experimental studies.
 Experimental studies can be used to determine whether 
a drug may impair driving-related functions and are most 
commonly performed for medicinal drugs using healthy 
individuals taking relatively small drug doses. In many 
countries it is impossible to perform experimental studies 
of illicit drugs in humans for ethical reasons. In countries 
where such studies are allowed, the doses given and 
drug exposure times are often lower than those used by 
problematic drug users and may therefore not refl ect the 
actual risks in road traffi c.
 The resulting effects of drug use on traffi c safety are a 
function of the degree to which the drugs are used, the levels 
and manners in which they are used, and the populations 
that are using them [86]. Therefore, epidemiological studies 
are needed to determine the actual consequences of drug 
use on road traffi c safety. 
 An important advantage with epidemiological studies 
is that they may be used to determine the impact of drug 
use in the general population of drivers, which includes 
users of illicit drugs, patients taking medicinal drugs for 
treatment of illness or relief from symptoms, and drivers 
using the same type of drugs for recreational purposes or 
because of drug addiction. In the latter case, the taken dose 
may be substantially higher than doses taken by patients 
for therapeutic purposes. Medicinal drugs that are used for 
the treatment of severe pain, anxiety, insomnia, narcolepsy, 
or hyperactivity are among those most frequently used for 
nontherapeutic purposes.
 This review is primarily based on articles found by 
searching the major scientifi c literature databases. We 
have only included studies published in English.
I. METHODOLOGICAL ISSUES
A. Challenges and Diffi culties
 There are four main types of epidemiological studies 
on the incidence and consequences of drug-impaired 
driving in various driving populations, primarily those 
involved in road traffi c crashes (RTCs): (a) cross-sectional, 
descriptive studies on the prevalence of drug use; (b) cohort 
and population studies on RTC involvement among drug 
users compared to non–drug users; (c) case-control studies 
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comparing drug use among RTC-involved and non–RTC-
involved drivers; and (d) studies on RTC-involved drivers 
only, such as responsibility studies and case-crossover 
studies. Results from cross-sectional studies may be used 
to propose hypotheses on RTC risk related to the use 
of individual medicinal or illicit drugs, whereas cohort 
studies, case-control studies, responsibility studies, and 
case-crossover studies are analytical studies that may be 
used to estimate the actual RTC risks associated with the 
use of individual drugs. 
 A general diffi culty in all types of epidemiological 
studies of RTCs is a possible selection bias in the inclusion 
of RTC-involved drivers. It is only possible to include 
drivers involved in RTCs that are recorded in databases 
or registries, self-reported RTC-involved drivers, injured 
drivers receiving treatment, drivers involved in RTCs that 
are subject to blood sampling for toxicological testing, or 
fatally injured drivers subject to legal autopsy. If including 
a control population, a selection bias may occur as well.
 Knowledge about alcohol and drug use may be 
incomplete for both those involved in accidents and for a 
control population of drivers who are not crash-involved. 
If data is based on self-reports, underreporting might be a 
signifi cant problem [1,37,54,89,113]. If basing the study 
on drug testing of biological samples, only cases where 
sampling is performed are included, and a limited number 
of psychoactive substances are looked for in most studies. 
Thus, the use of some drugs or drug combinations that 
can affect the results may not be detected.
 If information is obtained from prescription registries, 
the data just tells us that the medicinal drug has been 
dispensed at a pharmacy, not that it is actually taken and 
if so, taken in recommended doses. Another diffi culty 
is related to the fact that the patient has received the 
prescription for a medicinal drug due to illness or disease, 
which itself may affect the RTC risk. In fact, the patient 
might be a more dangerous driver in some cases of 
nonmedicated disease than when medication is taken. In 
studies using data from prescription registries, the use of 
alcohol and illicit drugs is not taken into consideration, 
as well as nonrecorded use of medicinal drugs.
 RTC involvement does not mean responsibility. In 
RTCs between a drug-impaired driver and a sober driver, 
the driver who is injured and therefore included in the 
study as RTC-involved might not be the one who was 
responsible for the RTC. This will cause a “dilution” of the 
calculated RTC risk, as previously described for alcohol 
in case-control studies [45]. Studies of only responsible 
drivers would eliminate this error. In some studies, drivers 
injured or killed in single-vehicle RTCs are investigated 
separately because they are almost always responsible in 
such cases.
 A low participation rate may give a signifi cant sampling 
bias. The refusal rate may be related to study design and/
or to cultural issues. It might be suggested that a large 
proportion of those who voluntarily participate in studies 
are conscientious individuals without signifi cant social or 
behavioral problems, whereas some of those who refuse to 
participate might be careless or might not want to reveal 
any less acceptable behavior. 
 Covariates (confounding or interacting variables) 
that are usually included in matching cases and controls 
or in data analysis are: age, gender, time of day/
week, and geographical region. Some other possibly 
important covariates are: driving experience, personality 
characteristics, state of physical and mental health, sleep 
deprivation, state of alertness, exhaustion, distractions, use 
of caffeine, hunger, thirst, socioeconomic factors, driving 
alone or with passengers, speed limit, weather conditions, 
visibility, traffi c density, the condition of the road, and the 
condition of the motor vehicle.
 Covariates related to personality are often not included. 
If cases and controls are different in relation to impulsivity, 
sensation-seeking and risk-taking behavior, the calculated 
risk for RTC involvement will not refl ect the risk posed by 
the drug alone, but a combination of substance use with 
personality factors. A particular problem is the association 
between the use of illicit drugs and risk-taking personality 
[10,14,33,65,119], which in itself may be associated with 
high RTC risk also in the absence of drug use. In addition, 
risk-taking behavior might again be increased after using 
some types of drugs.
 It is often diffi cult to relate any increased RTC 
risk to drug doses or blood drug concentrations in 
epidemiological studies due to lack of statistical power; 
therefore, assessments are in most studies performed using 
dichotomous data (drug used: yes/no). 
 It is important to remember that epidemiological 
studies cannot be used to prove causality; the studies can 
merely be used to document an association between drug 
use and involvement in RTCs. Any observed association 
may also, at least partly, be related to confounding factors 
that are not controlled for.
 Guidelines for research on drugged driving were 
published in 2008 [118]. They include recommendations 
for roadside surveys, studies of drivers injured in RTCs 
(hospital studies), fatal RTC studies, and the collection and 
analysis of biological samples. Similar recommendations 
for cohort studies or research using registries or self-
reported data have, to our knowledge, not been published. 
However, general guidelines on observational studies in 
epidemiology have been developed [116].
 More challenges and diffi culties that are specifi c for 
different study types are discussed in sections C-E.
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B. Cross-Sectional Studies
 The use of drugs by drivers who are involved in 
RTCs is investigated in descriptive cross-sectional 
studies. After alcohol, the most frequently found drugs 
are cannabis, benzodiazepines, stimulants, and opioids 
[30,51,72,73,91,105]. Combinations of alcohol and drugs 
or multiple drugs are also commonly found. We have not 
reviewed cross-sectional studies in this article.
C. Cohort and Population Studies
 RTC involvement among drivers who are using a 
specifi ed drug may be compared with RTC involvement 
among drivers who are not using the drug. The use 
of medicinal drugs can be studied by using data from 
prescription registries, and data on RTC involvement or 
injury may be obtained from accident registries or health 
databases. The date for dispensing from a pharmacy is 
regarded as the starting date for drug use. RTCs during the 
fi rst 7 or 14 days after dispensing date are often measured 
and compared with RTCs among drivers who have not 
purchased the same type of drug. The drug-using driver 
may be his own control; the number of RTCs during periods 
of drug use is then compared with RTCs during periods 
without using the drug in question. This type of study is 
called “case-crossover study” and is discussed in section 
E.
 The selection of the drivers in the drug-exposed and 
non–drug-exposed cohorts is independent of any RTC 
involvement; this is in contrast to case-control studies, 
where RTC-involved drivers are selected as cases, as well 
as in responsibility studies, where only RTC-involved 
drivers are studied.
 Studies of the association between self-reported use of 
medication or illicit drugs and RTCs are also performed. In 
those surveys, participants are selected by random within 
geographical areas and sometimes within specifi ed age 
groups by using population registries of different types, 
such as driver license, health, social insurance, or resident 
registries. Information is gathered by using questionnaires 
or telephone interviews. The frequency of drug use is 
recorded as well as involvements in RTCs under the 
infl uence of the drug in question and RTCs when not using 
the substance in question. A list of cohort and population 
studies published after 1998 is presented in Table 1.
D. Case-Control Studies
 Case-control studies are in general used to study the 
association between a defi ned exposure and an outcome 
of active exposure and are sometimes regarded as the 
optimal methodological approach for studying the RTC 
risk when driving after using alcohol or drugs [11,62]. 
This statement might be questionable due to a number of 
diffi culties, which we have discussed quite extensively 
below. However, there is no doubt that a well-performed 
case-control study of drug use and RTC involvement 
provides important information on the association between 
drugs and RTC risks among drivers in actual road traffi c. 
 Cases are drivers involved in RTCs. They may be 
selected from police records, insurance records, hospital 
records, postmortem autopsy records, other databases or 
registries on RTC-involved drivers, or by self-reported 
RTC involvement.
 Controls are drivers who are not involved in RTCs 
and may be selected from random traffi c, from driver’s-
license databases, or by self-reported noninvolvement in 
RTCs.
 The exposure to drugs may be determined in different 
ways: by analyzing drugs in biological samples (blood, 
oral fl uid, urine, or sweat), by self-reporting, or by using 
data from prescription registries.
 If using biological samples, blood or oral fl uid may 
be used to study real-time drug exposure (i.e., at the time 
of sample collection), whereas samples of sweat or urine 
may be used to detect drug use once or more during the 
last days or weeks, to study drug-using drivers (i.e., not 
only drug exposure at the time of sample collection).
 Normally, the odds ratios (ORs) for involvement in 
RTCs are calculated in case-control studies using logistic 
regression analysis. The reference group in the regression 
analysis may either be (a) drivers who have not used 
alcohol or any psychoactive drugs before driving; or (b) 
drivers who have not used the substance in question (but 
they may have used alcohol or other drugs). Those two 
calculation options give different ORs.
 Most often the OR is calculated for single drug use (i.e., 
not combined with alcohol or other drugs), but sometimes 
the OR is calculated for any use of that particular drug 
(either alone or in combination with alcohol or drugs). 
Previous studies have shown that those calculation methods 
may give very different ORs [46,48]. The chosen method 
is in some studies not properly described.
 An important requirement for case-control studies is 
that cases and controls must be selected by random from 
the same population; i.e., controls should be selected in an 
unbiased manner from those individuals who would have 
been included in the case series, had they been involved 
in an RTC [85]. To enable this, cases and controls should 
be matched regarding important covariates, or more 
commonly, covariates should be included in the data 
analysis. It is very diffi cult to control for all signifi cant 
factors. Therefore, the outcome of case-control studies 
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Table 1. Cohort and population studies of road traffi c crash (RTC) involvement among drug users and non-drug users 
Authors, year  Population size,  Substances
country, ref. Methodology survey, or cohort Data sourcea assessedb Covariatesc
Asbridge et al. Student survey 6,087 senior Questionnaire cand edu, exp, fak, sex
2005, Canada [3]  students or interview  urb
Bachs et al., 2009 Population study 3.1 million Prescription and codd, tra age, sex
Norway [5]  age 18–70 RTC DB
Bramness et al. Population study 3.1 million  Prescription and card, diad —
2007, Norway [20]  age 18–69 RTC DB sal
Bramness et al. Population study 3.1 million   Prescription and andd —
2008, Norway [22]  age 18–70 RTC DB
Bramness et al. Population study 3.1 million  Prescription and lit, val age, sex
2009, Norway [21]  age 18–70 RTC DB
Bramness et al. Population study 3.1 million   Prescription and mete age, sex
2012, Norway [19]  age 18–70 RTC DB
Engeland et al. Population study 3.1 million   Prescription and bend, bet age, sea, sex
2007, Norway [35]  age 18–69 RTC DB cra, nsad
    opid, pene
Fergusson & Horwood Birth cohort study 907, age 18–21  Questionnaire cand age, att, beh, ddb
2001, New Zealand [38]   or interview  exp, sex
Fergusson et al., 2008 Birth cohort study 936, age 18–21 Questionnaire can beh, dui, exp
New Zealand [39]   or interview
Gerberich et al., 2003 Healthcare cohort 64,657 Questionnaire cane age, bmi, dis, dri
US [43] study  or interview  edu, eth, mar, smo
Gustavsen et al. Population study 3.1 million   Prescription and hypd age, sex
2008, Norway [52]  age 18–69 RTC DB
Lai et al., 2014 Exposed and non- Exposed: 8,188 Health insurance zold age, dis, dru, sex
Taiwan [69] exposed cohorts non-exp.: 32,752 DB
Mann et al., 2007 Population survey 2,676   Questionnaire cand age, edu, inc, mar
Canada [79]   or interview  sex
Mann et al., 2010 Population survey 8,481   Questionnaire cand age, dri, edu, exp
Canada [80]   or interview  inc, mar, sex
Neutel, 1998 Population study 1 million Prescription, health bend age, alc, dru, sex
Canada [92]   insurance and
   hospital DB
Pulido et al., 2011 Population survey 17,484  Questionnaire cand, cocd age, alc, dru, edu
Spain [99]   or interview  eth, occ, exp, sex
Skurtveit et al., 2012 Population study 3.1 million Prescription and adbe  age, sex
Norway [110]  age 18–69 RTC DB
Stoduto et al., 2012 Population survey 8,107  Questionnaire cocd age, dui, exp, inc
Canada [112]   or interview  sex
Wadsworth et al. Population survey 4,754  Questionnaire cand age, dis, dri, edu
2006, UK [117]   or interview  inc, occ, per, sex
     smo
a Abbreviations for data sources:  DB = database or registry.
b Abbreviations for substances: adb = antidiabetics; and = antidepressants; ben = benzodiazepines; bet = beta blockers; can = cannabis; 
car = carisoprodol; coc = cocaine; cod = codeine; cra = calcium receptor antagonists; dia = diazepam; hyp = hypnotics; lit = litium; 
met = methadone; nsa = non-steroidal anti-infl ammatory drugs; opi = opioids; pen = pencillins; sal = salbutamol; tra = tramadol; val 
= valproate; zol = zolpidem.
c Abbreviations for covariates: age = age of driver; alc = alcohol used; att = attitudes to risky driving; beh = driving behavior; bmi = 
body mass index; ddb = drink driving behavior; dis = disease or health status; dri = drinking habits; dui = previous driving under the 
infl uence; dru = drug(s) used; edu = education grade; eth = ethnicity; exp = driver experience or milage; fak = used fake ID to get 
alcohol; inc = income; mar = marital status; occ = occupational status; per = personality; sea = season of the year; smo = smoking; 
urb: urbanity.
d Statistically signifi cant association between drug use and RTC was reported.
e Statistically signifi cant association was reported for some groups of drivers.
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seldom determines the increase in RTC risk due to only 
the drug per se, but instead the RTC risk posed by the drug 
user, which also includes behavioral and personality factors 
in addition to physical and mental health. Long-term drug 
abuse may also cause somatic and mental changes that 
may increase the RTC risk. Case-crossover studies (see 
section E) may be used to overcome this problem, at least 
partly, because important covariates such as age, gender, 
and behavioral and personality factors are the same.
 If using biological samples, blood samples should 
ideally be collected from both cases and controls because 
blood samples refl ect recent intake and exposure to drugs. 
Blood samples should be taken from cases immediately 
after RTCs to eliminate concentration changes due to 
metabolism or postmortem redistribution [40,53,104]. 
Blood samples are the best type of biological matrix for 
drug analysis that can be used for evaluation of RTC risk 
related to the drug concentration, which is expected to 
refl ect the drug concentration in the central nervous system 
and therefore most likely the degree of drug infl uence.
 The controls are drivers who are not involved in 
RTCs and who have the option of refusing to participate. 
Some drivers may refuse because of fear of detection 
and prosecution, whereas others may refuse because 
of the invasiveness or intrusiveness of the sampling or 
because they do not want to spend the amount of time 
required. The refusal rate is often particularly high when 
collecting blood samples; in recent roadside surveys of 
alcohol, drugs, and driving, the refusal rate was 24% in 
Lithuania; it was 52% when collecting blood or oral fl uid 
in Belgium, and 25% refused to give a blood sample but 
20% were willing to give a sample of oral fl uid instead 
of blood in the Netherlands [60]. In American roadside 
surveys, 50–60% refused to give blood samples [67,68]. 
 Oral fl uid has sometimes been collected from controls 
in case-control studies because it refl ects drug presence in 
blood [109,115]. When collecting oral fl uid, the refusal rate 
was less than 10% in roadside surveys in Denmark, Norway, 
Poland, Portugal, and Spain; however, it was higher in 
Sweden, Finland, the Czech Republic, and Hungary [60]. 
The refusal rates were about 20–30% in North American 
roadside surveys [8,64,68]. It has thus been possible to 
obtain high participation rates if collecting oral fl uid when 
using a good study design. However, other factors, such 
as cultural issues, may also have affected the participation 
rate.
 Because of different drug concentration in oral fl uid 
and blood, it can be diffi cult to compare the prevalence of 
drugs. However, the prevalence of a drug in paired samples 
of oral fl uid and blood from the same cohort are equal if 
using equivalent (not equal) cutoff concentrations [47,49], 
then the average drug detection time in oral fl uid will be 
the same as in blood. Equivalent cutoff concentrations 
for oral fl uid and blood have been used in a few previous 
studies [12,46,48,57]. If equivalent cutoff concentrations 
are not used, the OR for RTC involvement will either be 
overestimated or underestimated, depending on differences 
in drug detection times in oral fl uid and blood after intake 
of a single drug dose. Drug concentrations in oral fl uid 
cannot be used to accurately estimate concentrations in 
blood because of large inter- and intraindividual variations 
in drug-concentration ratios between oral fl uid and blood 
[70,120].
 Some studies have compared results for blood samples 
from cases with urine samples from controls or used a 
mixture of data from blood and urine samples [34,87,121].
That type of case-control design makes interpretation of 
results diffi cult, because a drug fi nding in urine does not 
indicate active drug exposure while driving. Urine samples 
may be positive for a drug and/or metabolites for a number 
of days longer than a blood sample, with very large variation 
between individuals, and it is therefore impossible to defi ne 
equivalent cutoff concentrations in blood and urine, and 
the calculated OR for RTC involvement may be very much 
underestimated. If using urine samples, urine should be 
collected from all cases and all controls. This type of study 
will determine any association between drug users and 
RTCs and not between active drug exposure and RTCs.
 Biological samples should be analyzed for a broad 
range of psychoactive substances. Multidrug use and 
combinations of alcohol and drugs is commonly observed 
among drivers injured or killed in RTCs [72,73,105] 
because it may increase impairment and thus also the RTC 
risk. If only analyzing for a small number of substances, 
multidrug use may not be detected and the calculated ORs 
may be incorrectly high, while risks related to drugs that 
are not analyzed will not be detected at all.
 Some studies have compared results for blood samples 
from cases with self-reported drug use among controls 
[15,55]. It is well known that underreporting of drug 
use is common and it may vary for different drugs and 
between different cohorts or cultures [1,37,54,89,113]. 
However, results of studies of this type may be used to 
propose hypotheses on increased RTC risk after using 
certain drugs.
 Houwing et al. recently discussed several random and 
systematic errors that may occur in case-control studies, 
such as sample size, low cell counts, geographical bias, 
sampling method, inclusion criteria, refusals, distributions 
of age and gender, time lapse between accident or 
apprehension and sample collection, analytical methods, 
and confounding factors [61].
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 It is practically impossible to fulfi ll the requirements 
for optimal case-control studies of drugs and RTCs. It is 
easy to handle some confounding factors, such as age, 
gender, time of day, day of week, and type of road or 
crash site, but more diffi cult to handle selection bias, 
low participation rate, and lack of control of important 
confounding factors. The calculated OR for involvement 
in an RTC will not only be related to risks posed by the 
substance per se, but very much affected by the study 
design, participation rate, confounding factors that are not 
adjusted for during matching or data analysis, and often an 
uncertainty introduced because of using different biological 
fl uids from cases and controls. Lists of case-control studies 
published in English after 1998 are presented in Tables 2 
and 3.
Table 2. Case-control studies using biological samples (cases were killed or injured in RTCs, controls were not involved in RTCs) 
Authors, year Participation Participation  Substances Substances
country, ref. Cases rate (%)a Controls rate (%)a Samplesb Cutoffsc analyzedd assessedd Covariatese
Assum et al. 87 killed or  Unk. 410 drivers in 87 Alcohol: B or BR  No alc, amp, ben, can ampf, benf, can
2005, Norway [4] injured car/van/  normal traffi c  Drugs: B (cases)   coc, ecs, opi mulf, opi
 minibus drivers    OF (controls)
Beirness et al. 902 fatally Unk. 4,711 drivers in 68.4 Alcohol: B or BR  No alc, amp, ben, can canf
2013, Canada [9] injured drivers  normal traffi c  Drugs: B (cases)   opi
     OF (controls)
Bogstrand et al. 96 injured car/ 93 5,305 drivers in  93.8 Cases: B  Yes alc, amp, ben, can  mulf age, sex
2012, Norway [17] van drivers  normal traffi c  Controls: OF  coc, ecs, opi, zhy  tim
       
Bogstrand & Gjerde 2,738 drivers Unk. 9,375 drivers in 94 Cases: B Yes alc, amp, ben, can  ampg, beng, cang  age, geo
2014, Norway [16] arrested for DUI  normal traffi c with   Controls: OF  coc, ecs, opi, zhy cocg, ecsg, mulg sea, sex 
 (BAC <0.2 g/L)  BAC <0.2 g/L     opig, zopg tim
 (794 RTC-
 involved)
Brault et al., 2004 512 killed 38.3 5,931 drivers in 49.6 Alcohol: B or BR Yes alc, amp, bar, ben ampf, bar, benf age, sex 
Canada [23] drivers  normal traffi c  Drugs: U  can, coc, opi, pcp canf, cocf, opif tim
 passenger cars      opi, pcp pcpf
Compton & Berning 3,095 drivers  79.6 6,190 drivers in 83.7 OF Yes alc, and, can, opi and, canf, opi age, geo
2015, US [25] involved in  normal traffi c    sed, sti   sedf, sti sea, sex
 RTC        tim
Gjerde et al., 2011 204 killed car/ 61 10,540 drivers in 88 Cases: B Yes alc, amp, ben, can  ampf, ben, can age, sea
Norway [48] van drivers  normal traffi c  Controls: OF  car, coc, ecs, opi can, mulf, zop sex, tim
       zhy 
Gjerde et al., 2013 508 killed car/ 61 9,210 drivers in 94 Cases: B Yes alc, amp, ben, can ampf, benf, can age, geo
Norway  [46] van drivers   normal traffi c  Controls: OF  coc, ecs, opi, zhy mulf, zop  sea, sex
         tim, urb
Hels et al., 2011  [56] 1,112 killed FI 94.3 21,917 drivers in FI 52 Alcohol: B or BR Yes alc, amp, ben, can  ampf, ben/ zhyf age, geo 
Bernhoft et al. 2012 [12] car/van drivers NO 59 normal traffi c NO 94 Drugs: B (cases)   coc, ecs, opi, zhy can, cocf, mulf sex
Europe (4 countries)  PT 79  PT 97 OF (controls)   opif
  SE 94  SE 62
Hels et al., 2011 [56] 2,490 injured BE 94.6 15,832 drivers in BE 48 Alcohol: B or BR Yes alc, amp, ben, can ampf, ben/zhyf age, geo 
Hels et al., 2013 [57] car/van drivers DK 95 normal traffi c DK 95 Drugs: B (cases)  coc, ecs, opi, zhy canf, coc, mulf sex
Bernhoft et al., 2012 [12]  FI 91.5  FI 52 B or OF (controls)   opif
Europe (6 countries)  IT 100  IT 100
  LT 100  LT 76
  NL unk.  NL 95
Hou et al., 2012 254 injured 93 254 76 Alcohol: B or BR  No alc, amp, and, bar and, bar, benf age, geo 
Taiwan [59] drivers    Drugs: B or U  ben, can, coc, opi  mar, sex
       pcp  tim
Kuypers et al., 2012 337 injured  27.0 2,726 drivers in 44.8 Alcohol: BR Yes alc, amp, ben, can  ampf, ben, canf age, sex
Belgium [66] car/van drivers  normal traffi c  Drugs: B  coc, ecs, opi, zhy coc, mulf, opi tim
        zhyf
Li et al., 2013 737 killed 35.6 7,719 drivers in 70.7 Alcohol: B or BR No alc, amp, and, anh canf, opif, mulf age, geo 
US [74] drivers  normal traffi c  Drugs: B or U (cases)   ben, can, car, coc stif  sex, tim
     OF (controls)  ecs, ket, opi, pcp
       zhy
Marquet et al., 1998 296 age 18–35 Unk. 278 age 18–35 Unk. Cases: U Yes amp, can, coc, ecs  canh, opi age, geo 
France [81] injured drivers  other patients  Controls: U  opi  sex
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E. Responsibility and Case-Crossover Studies
 Responsibility studies are case-case studies performed 
without any non-RTC control group. Judgments about 
responsibility for causing the RTC are made by examining 
the circumstances leading up to the RTC without having 
information about alcohol or drug use by the drivers, who 
are classifi ed according to their degree of responsibility 
for the RTC. Then drug use is compared for each category, 
and ORs for RTC responsibility are calculated for drug 
users. Blood samples should be used for all categories 
of RTC responsibility and the samples should be taken 
immediately after the RTC. The second-best alternative 
is to collect samples of oral fl uid. If collecting urine 
samples, drug intake during the last days or weeks is 
detected, not only active drug exposure at the time of the 
RTC. Some responsibility studies are using self-reported 
use of drugs, which may introduce diffi culties due to 
underreporting of drug intake, incorrect categorization of 
active drug exposure, or incorrect reporting of RTCs and 
RTC responsibilities. 
 As with case-control studies, a large number of 
psychoactive substances should be included in the analysis 
of blood samples to eliminate cases with additive effects 
due to multidrug use or combinations of alcohol or drugs. 
Ideally, drug concentrations in blood at the time of the 
RTC should be included in data analysis. However, this is 
diffi cult because of few cases within each relevant drug-
concentration interval.
 The judgment of responsibility, including any police 
judgments, may easily be biased, for example by suspicion 
or knowledge about current or previous alcohol or drug use, 
previous RTC involvement, traffi c violations, or criminal 
records. It is therefore important that this judgment is done 
in accordance with predefi ned criteria [28,103,108].
 A potential diffi culty is that RTC-involved drivers who 
are judged to have little or no responsibility for the RTC 
might not represent randomly selected drivers because they 
fail to avoid an RTC. This may be related to differences 
in signifi cant confounding factors regarding personality, 
sleep deprivation, alertness, health, alcohol or drug use, 
etc., and may introduce an error in risk estimates.
Mathijssen & Houwing 184 injured 88.9 3,374 drivers in 87.6 Alcohol: B or BR  No alc, amp, and benf, can
2005, Netherlands [82] drivers  normal traffi c  Drugs: B (cases)  ben, can, coc  cod, morf 
     B, U or Q (controls)  opi mulf
Movig et al., 2004 110 injured  Unk. 816 drivers in 79.3 Alcohol: B or BR  No alc, amp, and  amp, benf   age, sea  
Netherlands [87] drivers  normal traffi c  Drugs: B or U  bar, ben, opi can, coc sex, tim
        mulf, opi
Mura et al., 2003  900 injured  96 900 non–trauma 96 B and either U or SW Yes alc, amp, and benf, canf age, sex
France [88] drivers  patients    bar, ben, can morf
       coc, opi
Perttula et al., 2014 427 killed  Unk. 687 drivers at 63.4 Cases: B Yes anh anh age
Finland [97] drivers  petrol station  Controls: B, Q
Romano et al., 2014 1,766 killed  Unk. 3,424 drivers in 71 Alcohol: B or BR  No alc, amp, and canf, opi age, eth 
US [106] drivers  normal traffi c  Drugs: B or U (cases)   anh, ben, can stif sex
     OF (controls)  car, coc, ecs 
       ket, opi, pcp
       zhy
Woratanarat et al., 2009 200 injured  Unk. 849 drivers at Unk. Alcohol: B or BR  Yes alc, amp, and ampf, and
Thailand [121] drivers  petrol station  Drug: U, Q  ane, anh, bar anh, can
       ben, can, coc morf, mul
       mit, mus, opi
a Abbreviations for countries: FI = Finland; NO = Norway; PT = Portugal; SE = Sweden; BE = Belgium; DK = Denmark; IT = Italy; LT = Lithuania; NL = The 
Netherlands.
b Abbreviations for samples: B = blood; BR = breath; OF = oral fl uid; Q = questionnaire or interview; SW = sweat; U = urine.
c Equivalent cutoff for samples and controls.
d Abbreviations for substances: alc = alcohol; amp = amphetamines; and = antidepressants; ane = antiepileptics; anh = antihistamines; bar = barbiturates; ben = 
benzodiazepines; can = cannabinoids; car = carisoprodol; cod = codeine; coc = cocaine/metabolites; ecs = ecstacy (MDMA); ket = ketamine; mit = mitragynine; 
mor = morphine/heroin; mul = multiple drug use; mus = muscle relaxants; opi = opioids; sed = sedatives; sti = stimulants; zhy = z-hypnotics (zolpidem, 
zopiclone); zop = zopiclone.
e Abbreviations for covariates: age = age of driver; eth = ethnicity; geo = geographical area; mar = marital status; sea = season of the year; tim = time of day or 
week; urb = urbanity.
f Statistically signifi cant association between drug use and RTC was reported.
g Calculated ORs were not relative to sober drivers; ranks between ORs for arrest after using single or multiple drugs were calculated.
h Statistically signifi cant association was reported for some groups of drivers.
Table 2. (Continued)
Authors, year Participation Participation  Substances Substances
country, ref. Cases rate (%)a Controls rate (%)a Samplesb Cutoffsc analyzedd assessedd Covariatese
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 Case-crossover studies are comparing the number 
of RTCs for each individual during periods of drug use 
with periods without drug use. Each person in the study is 
both a case and his own self-matched control. This study 
design eliminates the need for matching cases and controls 
regarding a number of confounding factors that may affect 
the RTC risk. Periods of drug exposure may be based on 
either self-reported use or data recorded in prescription 
registries, whereas data on RTCs may be based on self-
reports or RTC registries.  An important diffi culty with 
this study design is that nontreated illness during periods 
with no drug use may bias the risk calculations. 
 A list of responsibility and case-crossover studies 
published in English after 1998 is presented in Table 4.
 Another problem is the inclusion of drivers involved in 
single-vehicle RTCs, who are virtually all responsible for 
their RTCs. It may not be relevant to compare those drivers 
with nonresponsible drivers, who are almost exclusively 
included in multiple-vehicle RTCs.
 A review of previous responsibility studies and 
diffi culties and faults has recently been published [108]. 
Diffi culties were often related to selection procedures, the 
defi nition of responsibility, the use of undocumented factors 
when assessing responsibility, lack of blinded exposure 
assessment, varying or missing data on the proportion of 
responsible drivers, and lacking discussion of confounding 
and mitigating factors.
Table 3. Case-control studies using questionnaires or registries (cases were drivers injured or involved in RTCs) 
Authors, year No. of cases Participation No. of Participation Data Substances
Country, ref. crash outcome  rate (%)a controls rate (%)a sourceb assessedc Covariatesd
Blows et al., 2005 571 involved in injurious 92.8 588 random 78.8 Alcohol: B or BR cane age, alc, bel  
New Zealand [15] or fatal RTC    Cannabis: Q  edu, eth, exp 
       pas, sex, spe
       tim, veh
Chang et al., 2012 5,183 injured n/a 31,093 matched n/a National health ins. andf, anp com, nop
Taiwan [24]   by age, sex, year  research DB benf, zhyf psy, urb
Delaney et al. 5,579 age 67–84 involved n/a 12,911 age 67–84   n/a Driver ins. & war age, dis,  dru
2005, Canada [27] in injurious RTC  not involved in  health ins. DB  rec, sex, urb
   injurious RTC
Etminan et al. 5,579 age 67–84 involved n/a 13,300 age 67–84 n/a Automobile & litf, caa age, dru, exp 
2004, Canada [36] in injurious RTC  drivers  health ins. DB  geo, rec, sex
Gomes et al., 2013 5,300 injured n/a 5,300 matched n/a Prescription & opif age, dru, pat
Canada [50]     health DB  ppv, sex
Hemmelgarn et al. 5,579 age 67–84 involved n/a 13,300 age 67–84 n/a Car ins. &  adbf age, geo, ins
2006, Canada [58] in injurious RTC    health DB  rec, sex
Johnell et al., 2014 30,845 age 50–80 involved in n/a 123,380 matched n/a Prescription & benf alc, age, dru 
Sweden [63] non-alcohol injurious RTC  by age, sex, geo  RTC DB  mar, occ, sex
McGwin et al. 447 age 65+ involved in RTC 79.8 454 matched by 74.1 Q acef, adb, ancf  age, eth, exp 
2000, US [83]   age, sex   and, bet, ben sex
      nsaf
Ravera et al., 2011 3,963 injured n/a 18,828 matched n/a Prescription & andf, anp, anxf dru
Netherlands [101]     RTC DB hypf, sed
a n/a = not applicable or not known.
b Abbreviations for data sources: B = blood; BR = breath; DB = database or registry; Q = questionnaire or interview.
c Abbreviations for substances: ace = angiotensin converting enzyme inhibitors; adb = antidiabetics; anc = anticoagulants; and = antidepressants; 
anp = antipsychotics; anx = anxiolytics; ben = benzodiazepines; bet = beta blockers; caa = carbamazepine; can = cannabinoids; hyp = 
hypnotics; lit = litium; nsa = non-steroidal anti-infl ammatory drugs; opi = opioids; sed = sedatives; war = warfarin; zhy = z-hypnotics 
(zolpidem, zopiclone). 
d Abbreviations for covariates: age =  age of driver; alc = alcohol used; bel = seatbelt use; com = comorbidity score; dis = disease or health 
status; dru = drug(s) used; edu = education grade; eth = ethnicity; exp = driver experience or milage; geo =  geographical area; ins = insulin 
use; mar = marital status; nop = non-psychiatric outpatient visits; occ = occupational status; pas = passengers in car; pat = previous alcoholism 
treatment; ppv = previous physician visits; psy = psychiatric outpatient visits; rec = previous driving records; spe = speed; tim = time of day 
or week; urb: urbanity; veh = vehicle age. 
e Statistically signifi cant association was reported for some groups of drivers. 
f Statistically signifi cant association between drug use and RTC was reported.
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Table 4. Studies of only RTC-involved drivers
Authors, year    Substances Substances
country, ref. Methodology Drivers Data sourcea analyzedb assessedb Covariatesc
Asbridge et al. Case-crossover 860 injured in RTC B, Q alc cand  ben, coc
2014 Canada [2]
Barbone et al. Case-crossover 19,386 RTC-involved  Prescription & n/a and, bend 
1998 UK [6]   RTC DB
Bedard et al. Recorded unsafe 32,543 killed in RTC B or U alc, amp, ben, can canf age, alc, rec, sex
2007, US [7] driving actione   FARS DB coc, opi, opd
Corsenac et al. Responsibility 72,685 involved in Police & n/a bupd, metd age, alc, dis, dru
2012, France [26]  injurious RTC health Ins. DB   geo, inj, occ, sex 
      tim, vet
Drummer et al. Responsibility 3,398 killed in RTC B, police crash alc, amp, ben, can ben, cand age, alc,  geo, sex
2004, Australia [29]   reports coc, ecs, opi opi, stig sin, yea
Dubois et al. Recorded unsafe 72,026 involved in non- B or U alc, amp, ben, can benf,h age, dru, rec, sex
2008, US [32] driving actione alcohol fatal RTC FARS DB coc, opi, opd
Dubois et al. Recorded unsafe 72,026 involved in non- B or U alc, amp, ben, can opif,g age, dru, rec, sex
2010, US [31] driving actione alcohol fatal RTC FARS DB coc, opi, opd
Gadegbeku et al. Responsibility 6,932 involved in fatal Alcohol: B if BR+ alc, amp, can, coc amp, cand age, sex
2011, France [41]  RTC Drugs: B if U+ opi coc, opi
   RTC DB
Gates et al. Recorded unsafe 8,325 male truck drivers B or U alc, amp, ben, can can, opif age, dru, rec 
2013, US [42] driving actione involved in non-alcohol FARS DB coc, opi, opd stif
  fatal RTC
Gibson et al. Case-crossover 49,821 involved in RTC Health DB n/a andh,i, anhi  
2009, UK [44] Case-series    bend, bet,
     hyph,i, opid
Laumon et al. Responsibility 10,748 killed in RTC Alcohol: B if BR+ alc, amp, can coc cand age, alc, tim, vet
2005, France [71]   Drugs: B if U+ opi
   RTC DB
Longo et al., 2000 Responsibility 2,500 injured in RTC B, police crash alc, ben, can, sti can, sti
Australia [76]   reports
Longo et al., 2001 Responsibility 2,500 injured in RTC B, police crash alc, ben, can, sti bend
Australia [77]   reports
Lowenstein & Responsibility  414 injured in RTC U alc, amp, bar, ben can age, bel
Koziol-McLain   RTC DB can, coc, lsd, mep  sex, tim
2001, US [78]    opi, pcp, xyl
Meuleners et al. Case-crossover 616 age 60+ Prescription & n/a andd, bend  age, dis, eth, geo
2011, Australia [84]  injured in RTC hospital DB  opid mar, sex
Orriols et al. Case-crossover 72,685 drivers involved Health ins. &  n/a hyph age, alc, dis, dru
2011, France [94] Responsibility in injurious RTC police DB   geo, occ, sev, sex
   police reports   tim, vet
Orriols et al. Case-crossover 72,685 drivers involved Health Ins. &  n/a andd age, alc, dis, dru
2012, France [95] Responsibility in injurious RTC police DB   geo, occ, sev, sex
   police reports   tim, vet
Orriols et al. Case-crossover 72,685 drivers involved Health ins. &  n/a aned age, alc, dis, dru
2013, France [93] Responsibility in injurious RTC police DB   geo, occ, sev, sex
   police reports   tim, vet
Orriols et al. Case-crossover 2,919 age 66–84 Car ins. &  n/a andd
2013, Canada [96]  Antidepressants used at health ins. DB
  day of RTC
Poulsen et al., 2014 Responsibility 1,046 killed in RTC B, police crash alc, amp, ben, can can age, lic, sex, sin
New Zealand [98]   reports ecs, opd, opi  urb, vet
Rapoport et al. Case time-to- 159,678 drivers age 65+ Health ins. & n/a andg, anf dru, lic, sex
2011, Canada [100] event  RTC DB  anpd, bend
     muld, ppi
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Reguly et al. Recorded unsafe 8,325 male truck drivers B or U alc, amp, ben, can opif age, dru, rec 
2014, US [102] driving actione killed in non-alcohol RTC FARS DB coc, opd, opi  sex
Sagberg, 2006 Responsibility 4,448 RTC-involved Q n/a andd age, dis, exp
Norway [107]
Soderstrom et al. Responsibility 2,537 injured in RTC Alcohol: B Not specifi ed can, cocd age, sex
2005, US [111]   Drugs: U
   Hospital DB
   RTC DB
van Elslande et al. Recorded unsafe 174 THC-positive & 174 B, RTC DB alc, can, opd canf age, sex
2012, France [114] driving actione matched killed drivers (no
  alcohol or drugs detected)
Yang et al., 2011 Case-crossover 1 million Health ins.  n/a bend, zhyd
Taiwan [122]   research DB
a Abbreviations for data sources: B = blood; BR = breath; DB = database or registry; Q = questionnaire or interview; U = urine; FARS = Fatality 
Analysis Reporting System, an US database operated by the National Highway Traffi c Safety Administration.
b Abbreviations for substances: alc = alcohol; amp = amphetamines; and = antidepressants; ane = antiepileptics; anf = antifungal drugs; anh = 
antihistamines; anp = antipsychotics; bar = barbiturates; ben = benzodiazepines; bet = beta blockers; bup = pubrenorphine; can = cannabinoids; 
coc = cocaine/metabolites; ecs = ecstacy (MDMA); hyp = hypnotics; mep = meprobamate; met = methadone; mul = multiple drug use; opd = 
other psychoactive drugs; opi = opioids; ppi = proton pump inhibitors; sti = stimulants; xyl = xylene; zhy = z-hypnotics (zolpidem, zopiclone); 
n/a = not applicable.
c Abbreviations for covariates: age = age of driver; alc = alcohol used; bel = seatbelt use; dis = disease; dru = drug(s) used; eth = ethnicity; exp = 
driver experience or milage; geo = geographical area; inj = previous injuries; lic = driver license status; mar = marital status; occ = occupational 
status; rec = previous driving records; sev = injury severity; sin = single vehicle crash; tim = time of day or week; urb: urbanity; vet = vehicle 
type; yea = year of crash.
d Statistically signifi cant association between drug use and RTC responsibility.
e Proxy measure for RTC responsibility.
f Statistically signifi cant association between drug use and unsafe driving action.
g Statistically signifi cant association for some groups of drivers.
h Statistically signifi cant association for some drugs.
i For long-term use. 
II. RESULTS
A. Study Quality
 Many large studies based on registry data have been 
performed. The quality of those studies depends primarily 
on the quality and completeness of the registries, both 
regarding RTCs and drug use. The individual use of alcohol, 
illicit drugs, and medicinal drugs obtained on the illicit 
market is not included in those registries and may cause 
a study bias.
 Many large population surveys have also been 
performed. It is well known that both the use of drugs and 
involvement in RTCs is often underreported, particularly 
the use of illicit drugs [1,37,54,89,113]. In many studies, the 
participants have not been asked about the use of alcohol 
or important drug groups, only selected drugs, e.g., only 
cannabis. Most surveys have not included factors related 
to alcohol or drug behavior, other behavioral factors, or 
personality factors, which may be important confounders.
 The largest and best-performed case-control studies 
on drugs and RTC involvement were part of the European 
Project DRUID (Driving Under the Infl uence of Drugs, 
Alcohol and Medicines) [12,56,57] and complied with most 
of the recommendations published by Walsh et al. [118]. 
Some small studies were also well performed; however, 
the statistical power was weaker in those studies due to 
small numbers of cases and controls.
 Three large case-control studies have also been 
performed in the US [25,74,106]. However, two of them, Li 
et al. [74] and Romano et al. [106], were not in accordance 
with the most critical recommendations for research on 
drugged driving [118]. The cases were selected from the 
US Fatality Analysis Reporting System (FARS) database, 
whereas the controls were selected from the 2007 roadside 
survey [68]. The FARS database has limitations that do 
not allow calculation of reliable estimates of the risk of 
RTC involvement resulting from drug use [13,25]. This 
is due to many factors, including inconsistent drug testing 
between states, a bias in selecting cases for drug testing 
Table 4. (Continued)
Authors, year    Substances Substances
country, ref. Methodology Drivers Data sourcea analyzedb assessedb Covariatesc
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zolpidem in Taiwan and found increased risk for major 
injury (hazard ratio (HR) 1.67, 95% CI 1.19–2.34); the 
risk increased with increasing dosage.
 Bernhoft et al. [12] and Hels et al. [56,57] (see 
Table 2) found in the two DRUID case-control studies a 
signifi cant association between the use of benzodiazepines 
or z-hypnotics and being injured (OR 1.77, 95% CI 
1.16–2.69) or killed (OR 4.59, 95% CI 3.28–6.43) [56,57] 
in RTCs. The Belgian part of the DRUID case-control 
studies published by Kuypers and co-workers [66] found 
a signifi cant association between the use of z-hypnotics 
and being injured (crude OR 6.45, 95% CI 1.63–25.52) 
but no signifi cant association for benzodiazepines.
 Gjerde and coworkers [46] found significant 
association between the use of only one benzodiazepine 
drug and being killed in an RTC (OR 8.8, 95% CI 4.7–16.5), 
and similar results for using only diazepam (OR 6.4, 95% 
CI 2.5–16.7). No signifi cant association was found for the 
use of only zopiclone and fatal injury among drivers.
 Signifi cant associations between benzodiazepine use 
and being injured or killed in RTCs were found in case-
control studies by Assum et al. [4] (OR 12.6, 95% CI 
1.3–122.8), Brault et al. [23] (OR 3.9, 95% CI 2.5–6.1), 
Hou et al. [59] (OR 3.41, 95% CI 1.76–6.70), Mathijssen 
and Houwing [82] (OR 2.98, 95% CI 1.31–6.75), Movig 
et al. [87] (OR 5.05, 95% CI 1.82–14.04) and Mura et al. 
[88] (OR 1.7, 95% CI 1.2–2.4).
 Chang and co-workers [24] found in a population-based 
case-control study (see Table 3) an adjusted OR of 1.64 
(95% CI 1.43–1.88) for an RTC after one week’s use of 
benzodiazepines and an OR of 1.37 (95% CI 1.06–1.75) 
for z-hypnotics. Johnell et al. [63] found in a Swedish 
study an OR of 1.26 (95% CI 1.17–1.36) for involvement 
in an injurious RTC after using benzodiazepines and no 
combination with other drugs.
 Ravera et al. [101] performed a case-control study in 
the Netherlands using prescription data linked with police 
RTC data and driving license data. A signifi cant association 
was found between the use of hypnotic benzodiazepines 
with intermediate half-life and involvement in an RTC (OR 
6.44, 95% CI 1.44–28.78), but no signifi cant associations 
were found for other hypnotics or sedatives.
 Gibson et al. [44] (see Table 4) performed a case-
series study in the UK; an incidence rate ratio (IRR) of 
1.94 (99% CI 1.62–2.32) was found for benzodiazepines 
in the fi rst four weeks of treatment and increased with 
extended exposure. Short-term use of z-hypnotics was not 
associated with an increased RTC risk, but longer-term use 
was associated with a modest increased risk (IRR 1.37, 
95% CI 1.05–1.79).
(only about half of fatal-RTC drivers are tested for drugs), 
failure to record all drug fi ndings in the database, and data 
on drug fi ndings were based on either blood or urine testing 
with cutoff concentrations not specifi ed. In addition, the 
cutoff concentrations in blood from cases and oral fl uid 
from controls were not equivalent; for some drugs the 
cutoffs for oral fl uid testing were therefore too low and for 
others too high compared to those used for blood. Those 
issues introduced unpredictable errors in the studies. The 
calculated ORs would certainly have been different if only 
blood samples had been collected for cases and controls.
 The third large US case-control study was performed 
in Virginia Beach, VA [25]. This study might have been 
better designed, but details had not been published by the 
time this review was prepared.
 Some other studies used partly blood and partly urine 
samples and in one study only sweat samples were collected 
from some participants; this makes interpretation of data 
diffi cult. 
 Problems mentioned above pertaining to study quality 
are referred to for some of the studies that are presented 
below. 
 We have primarily included peer-reviewed articles. We 
have only included studies that accurately specifi ed drugs 
or drug groups; studies on the association between RTCs 
and the use of “prescribed drugs”, “psychoactive drugs”, 
or “CNS drugs” without specifying which groups were 
excluded. Studies from 1998 discussed in the previous 
review article by Mørland [90] have not been included 
in this update.
B. Road Traffi c Crash (RTC) Risk Associated with 
Drug Use
1. Benzodiazepines and z-Hypnotics
 Engeland and co-workers [35] performed a population 
study using Norwegian prescription and RTC databases 
(see Table 1). They found an increased RTC risk during the 
fi rst seven days after patients started using benzodiazepines 
(standardized incidence ratio [SIR] of 2.9, 95% CI 
2.5–3.5 for tranquillizers and SIR 3.3, 95% CI 2.1–4.7 
for hypnotics). A similar increased risk was found by 
Bramness and co-workers [20] for patients starting to use 
diazepam (SIR 2.8, 95% CI 2.2–3.6).
 Gustavsen et al. [52] used Norwegian databases to 
study RTCs during the fi rst week after a hypnotic drug 
was dispensed. The largest risk increase was observed 
for fl unitrazepam (SIR 4.0, 95% CI 2.4–6.4), followed 
by nitrazepam (SIR 2.7, 95% CI 1.8–3.9), and lowest for 
z-hypnotics (zopiclone and zolpidem; SIR 2.3, 95% CI 
2.0–2.7). Lai and co-workers [69] studied patients using 
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 Longo et al. [77] found in a responsibility study 
that drivers who tested positive for benzodiazepines had 
a higher culpability rate than drug-free drivers. They 
also found a signifi cant linear relationship between 
benzodiazepine concentration and culpability for drivers 
who tested positive for benzodiazepines alone.
 Meuleners and co-workers [84] performed a 
population-based case-crossover study of older drivers 
based on data from registries and found that benzodiazepine 
users had an OR of 5.3 (95% CI 3.6–7.8) for hospitalization 
due to RTC.
 Rapoport et al. [100] found a signifi cant association 
between benzodiazepine use and RTC involvement among 
elderly drivers (HR 1.05, 95% CI 1.03–1.07) in a case-
only, time-to-event study.
 Yang et al. [122] performed a case-crossover study 
based on data from the Taiwanese health insurance research 
database and found an OR for RTCs of 1.74 (95% CI 
1.25–2.43) after taking one defi ned daily dose of zolpidem, 
OR 1.55 (95% CI 0.98–2.45) for zopiclone, OR 1.74 (95% 
CI 1.26–2.40) for long half-life benzodiazepines, and OR 
1.13 (1.04–1.23) for short half-life benzodiazepines.
 Dubois et al. [32], using the FARS database, studied 
unsafe driving actions among drivers killed in RTCs. 
Compared with drivers not using benzodiazepines, drivers 
taking intermediate or long-half-life benzodiazepines 
demonstrated increased odds for an unsafe driving 
action from ages 25 to 55. Drivers taking short-half-life 
benzodiazepines did not demonstrate increased odds.
 Orriols et al. [94] found in a French registry-based 
responsibility study that the risk for being responsible for 
an RTC was higher in users of benzodiazepine hypnotics 
(OR 1.39, 95% CI 1.08–1.79) and among drivers to whom 
a dosage of more than one pill of zolpidem a day had been 
dispensed during the fi ve months before an RTC (OR 
2.46, 95% CI 1.70–3.56); no association was found for 
zopiclone and risk of an RTC.
 Compton and Berning [25] found that RTC-involved 
drivers were signifi cantly more likely to test positive for 
sedatives in the recent large case-control study in Virginia 
Beach, VA. However, if adjusting for age, gender, ethnicity, 
and presence of alcohol, the OR for RTC involvement was 
not statistically signifi cant. Drummer and co-workers [29] 
found no signifi cant association between benzodiazepine 
use and RTC responsibility; however, the number of cases 
was small, so the study had low statistical power.
 Gjerde et al. [48] found, in another small study, no 
signifi cant associations between a single use of diazepam, 
any benzodiazepine, or zopiclone, probably because of 
lower statistical power. However, signifi cant associations 
were found for any use of those substances (alone or in 
combination with other drugs or alcohol).
 McGwin et al. [83] found, in an American case-
control study based on registry data, a weak although not 
statistically signifi cant association; OR of 5.2 (95% CI 
0.9–30.0).
2. Cannabis
 Asbridge et al. [3] (Table 1) studied the association 
between self-reported driving under the infl uence of 
cannabis with RTCs among senior students. A statistically 
signifi cant association was found; the adjusted OR was 
2.39 (p <0.001).
 Fergusson and Horwood [38] studied the association 
between cannabis use and RTC involvement in a young 
birth cohort in New Zealand. They found a statistically 
signifi cant relationship between reported annual cannabis 
use and RTC rates (p <0.001). They concluded that the risk 
appeared to refl ect the characteristics of the cannabis users 
rather than the effect of cannabis use on driver performance. 
In a second study of the same cohort published seven years 
later [39], the investigators found a marginally signifi cant 
association (p = 0.064) between driving under the infl uence 
of cannabis and RTCs after adjustment for annual distance 
driven and self-reported risky behaviors.
 Gerberich et al. [43] found a signifi cant association 
between current marijuana use and hospitalization due to 
RTCs among men (IRR 1.96, 95% CI 1.23–3.14) but no 
statistically signifi cant association for women (IRR 1.23, 
95% CI 0.71–2.05). However, the total number of RTCs 
was only 188 (100 for men and 88 for women), so the 
statistical power of this study was not very high.
 Mann et al. [79] found a signifi cant association 
between self-reported cannabis use more than once a 
week and self-reported RTC involvement (OR 2.76, 95% 
CI 1.50–5.08) in a Canadian population survey. They 
also found a signifi cant association between self-reported 
driving within an hour after cannabis use and RTC (OR 
2.61, 95% CI 1.45–4.68). They found similar results in 
a study performed three years later using a larger dataset 
[80]; the OR for self-reported collision after cannabis use 
was 1.84 (95% CI 1.23–2.76).
 In a Spanish national survey, Pulido et al. [99] found a 
signifi cant association between self-reported cannabis use 
more than four days per week and self-reported RTC injury 
(OR 1.6, 95% CI 1.0–2.6) but no signifi cant association 
for less frequent use.
 In a study in Wales using postal questionnaires, 
Wadsworth and co-workers [117] found that cannabis use 
during the previous year was associated with involvement 
in RTCs (OR 1.92, 95% CI 1.04–3.54).
 The DRUID case-control studies published by 
Bernhoft et al. [12] and Hels et al. [56,57] (Table 2) found 
a signifi cant association between THC and RTC injury (OR 
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1.91, 95% CI 1.15–3.17), but no statistically signifi cant 
association with fatal RTCs (OR 1.25, 95% CI 0.45–3.51) 
[12,56]. For the Belgian part of the DRUID study using 
blood samples from cases and controls [66], a very high 
OR of 13.40 (95% CI 3.95–45.42) for involvement in 
injurious RTCs was calculated.
 In American case-control studies, Li et al. [74] and 
Romano et al. [106] found signifi cant crude ORs of 
1.83 (95% CI 1.39–2.39) and 1.55 (95% CI 1.42–1.94), 
respectively. Compton and Berning [25] found that THC 
was associated with a signifi cantly elevated risk of RTCs, 
with a crude OR of 1.25. However, when adjusting for 
age, gender, ethnicity, and presence of alcohol, the OR 
was not statistically signifi cant.
 Beirness et al. [9] found in a case-control study using 
data from British Columbia, Canada, an OR of 4.95 (95% 
CI 3.70–6.62). The study is not very well described and 
the cutoff concentrations in oral fl uid for controls and 
blood for cases were most likely not equivalent.
 Brault et al. [23] found in a Canadian case-control study 
using urine samples an OR for fatal RTCs associated with 
cannabis alone of 1.6 (96% CI 1.1–2.4); for all cannabis 
cases (with or without other substances) the OR was 4.5 
(95% CI 3.3–6.0).
 Mura et al. [88] found in a French case-control study 
a signifi cant association between cannabis and RTC injury 
for THC (OR 2.5, 95% CI 1.5–4.2) when analyzing blood, 
urine, or sweat samples.
 Marquet et al. [81] found signifi cant difference in 
cannabis fi ndings in urine samples from female drivers 
involved in RTCs in France compared to non-trauma 
patients (p = 0.02) but not for male drivers; however, the 
number of cases (n = 296) and controls (n = 278) were low, 
giving low statistical power, and the study was fl awed as 
alcohol and sedative therapeutic drugs were not analyzed.
 Blows and coworkers [15] (Table 3) found in a 
population-based case-control study in New Zealand 
based on self-reported data that there was no signifi cant 
association between acute marijuana intake and RTC 
injury (OR 0.8, 95% CI 0.2–3.3), whereas there was a 
strong association between habitual use and RTC injury 
(OR 9.5, 95% CI 2.8–32.3). The authors concluded that 
the nature of this relationship was unclear.
 Asbridge et al. [2] (Table 4) found in a Canadian 
case-crossover study using blood sample analysis and 
self-reported data that cannabis used was associated with 
a fourfold increased odds of an RTC (OR 4.11, 95% CI 
1.98–8.52), whereas a regression relying on self-reports 
measures found no signifi cant association.
 Bedard and coworkers [7] found in a study of drivers 
killed in RTCs using data from the American FARS 
database that the presence of cannabis in biological 
samples was associated with signifi cantly increased odds 
for potentially unsafe driving action (OR 1.29, 95% CI 
1.11–1.50).
 Drummer and coworkers [29] found in an Australian 
responsibility study that drivers with THC in their blood 
had a signifi cantly higher likelihood of being culpable for 
an RTC than drug-free drivers (OR 2.7, 95% CI 1.02–7.0); 
for drivers with THC concentrations of 5 ng/mL or higher 
the OR was 6.6 (95% CI 1.5–28.0). Gadegbeku et al. [41] 
found an OR of 1.89 (95% CI 1.43–2.51) and Laumon 
et al. [71] found an OR of 3.32 (95% CI 2.63–4.18) for 
cannabis in similar responsibility studies in France; ORs 
in relation to THC concentration intervals were presented 
in both studies.
 Van Elslande et al. [114] found that drivers who were 
killed in RTCs with THC in blood (and no detection of 
other drugs or alcohol) had signifi cantly higher rates of 
driving failures than matched controls, i.e., fatally injured 
drivers without any alcohol or drugs detected in their blood 
test. The THC-positive drivers had signifi cantly lower 
levels of attention (p <0.01) and signifi cantly higher level 
of risky driving (p <0.01) as well as signifi cantly higher 
frequencies of other failures.
 Assum et al. [4] found no signifi cant association 
between cannabis use and RTC involvement in their 
case-control study. However, the number of cases (n = 87) 
and controls (n = 410) were far too low to give suffi cient 
statistical power; in addition, the cutoff concentrations in 
oral fl uid and blood were not equivalent.
 Gjerde et al. [46,48] found no signifi cant associations 
between THC and fatal RTCs after using only cannabis 
in two Norwegian studies (OR 0.9, 95% CI 0.1–7.3; and 
OR 1.9, 95% CI 0.8–4.6), probably due to low statistical 
power, but signifi cant associations if also including cases 
and controls with THC in combination with other drugs 
(OR 8.6, 95% CI 3.9–19.3; and OR 8.9, 95% CI 5.2–15.4).
 Gates and co-workers [42] found in a study of data on 
truck drivers involved in fatal RTCs based on the American 
FARS database an OR of 1.14 (95% CI 0.84–1.53) for 
performing an unsafe driving action associated with 
cannabinoids, which was detected by either blood or urine 
testing.
 Mathijssen and Houwing [82] found, in a Dutch study 
using blood samples from cases and urine or blood samples 
from controls, no statistically signifi cant association with 
RTCs. Urine samples may be positive for cannabinoids 
for weeks after use. Thus, urine samples are particularly 
unsuitable for case-control studies on the association 
between cannabis use and RTCs, except if only urine 
samples are collected from both cases and controls. 
Therefore, this study design gives incorrect risk estimates. 
The number of included cases was low (n = 184).
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 Movig et al. [87] found no signifi cant association 
between cannabis use and RTC involvement in their case-
control study. They collected either blood or urine from 
cases and controls. The fraction giving urine samples was 
signifi cantly higher among controls (85%) than cases 
(39%), thereby underestimating the calculated ORs because 
urine samples are positive for drugs for a signifi cantly 
longer time period than blood samples after drug use. In 
addition, the number of cases was low (n = 110), giving 
poor statistical power.
 Woratanarat et al. [121] collected urine from both cases 
and controls. Very few samples from cases and controls 
were positive for cannabis, and no signifi cant association 
between cannabis use and RTCs was found. As only urine 
samples were used, the study did not determine cannabis 
use immediately prior to the RTC but rather cannabis use 
during the last week(s).
 Longo et al. [76] found no signifi cant association 
between THC and responsibility for an RTC in an Australian 
study. In the US, Lowenstein and coworkers [78] found 
no signifi cant association between cannabis in urine and 
RTC responsibility.
 Poulsen and coworkers [98] found only a weak 
association, although not statistically signifi cant, between 
THC alone in blood and culpability for fatal RTCs in New 
Zealand (OR 1.3, 95% CI 0.8–2.3) when studying 1,046 
fatally injured drivers.
 Soderstrom and coworkers [111] found neither a 
signifi cant association between cannabis in urine and 
culpability for an RTC in a study of more than 2,500 
drivers in Maryland.
3. Opioids
 A Norwegian population study published by Engeland 
et al. [35] (Table 1) linking data from prescription registries 
with RTC databases found increased risk for involvement 
in RTCs among patients using natural opium alkaloids 
(SIR 2.0, 95% CI 1.7–2.4). Another Norwegian study 
by Bachs et al. [5] found signifi cant increased RTC risk 
among patients using codeine (SIR 1.9, 95% CI 1.6–2.2) 
but no signifi cant accident risk associated with the use of 
tramadol (SIR 1.5, 95% CI 0.9–2.3). Bramness et al. [19] 
found that male opioid maintenance treatment patients 
using methadone had increased RTC risk (SIR 2.4, 95% CI 
1.5–3.6) but no signifi cantly increased risk was observed 
for female patients. 
 Bernhoft, Hels, and coworkers (Table 2) [12,56,57] 
found in the European DRUID case-control studies an 
OR for being injured after using medicinal opioids of 
7.37 (95% CI 4.99–10.88) and for being killed an OR of 
4.07 (95% CI 2.14–7.72) [12, 56]. For illicit opiates, the 
OR was not statistically signifi cant for injured drivers, 
whereas for killed drivers, the OR was 10.04 (95% CI 
2.04–19.32).
 Signifi cantly increased risks for RTCs were also 
found in case-control studies by Brault et al. [23] for all 
opiate cases (OR 3.1, 95% CI 1.5–6.5), Mura et al. [88] 
for morphine (OR 8.2, 95% CI 2.5–27.3), Woratanarat et 
al. [121] for morphine (OR 27.97, 95% CI 9.77–80.08), 
Mathijssen and Houwing [82] for morphine/heroin (OR 
32.4, 95% CI 1.78–592) and Li et al. [74] for narcotic 
analgesics (crude OR 3.03, 95% CI 2.00–4.48).
 Gomes et al. [50] (Table 3) found in a Canadian 
population-based nested case-control study a statistically 
signifi cant association between opioid dose and risk for 
RTC trauma among drivers; the OR was 1.29 (95% CI 
1.06–1.57) for moderate doses and 1.42 (95% CI 1.15–1.76) 
for high doses.
 Meuleners and co-workers [84] (Table 4) found in an 
Australian case-crossover study based on prescription and 
hospital databases a signifi cant risk for injurious RTCs 
among older patients using opioid analgesics (OR 1.5, 
95% CI 1.0–2.3). Reguly and coworkers [102] found in 
a study using data from the American FARS database that 
male truck drivers using opioid analgesics involved in 
fatal RTCs had greater odds of committing unsafe driver 
actions (OR 2.80, 95% CI 1.64–4.81).
 Corsenac et al. [26] (Table 4) used data from three 
French national databases and performed responsibility and 
case-crossover analyses. Drivers who had been exposed 
to methadone and/or buprenorphine on the same day as an 
RTC had signifi cantly higher odds for being responsible 
for the crash (OR 2.02, 95% CI 1.40–2.91).
 Dubois and coworkers [31] found, in a study based on 
data from the American FARS database, that female drivers 
who tested positive for opioid analgesics demonstrated 
increased odds for performing an unsafe driving action 
from age groups 25–34 years (OR 1.35, 95% CI 1.05–1.74) 
to 55–64 years (OR 1.30, 95% CI 1.07–1.58); for male 
drivers this was true from age groups 25–34 years (OR 
1.66, 95% CI 1.32–2.09) to 65–74 years (OR 1.39, 95% 
CI 1.17–1.67). 
 Gibson and coworkers [44] found, in a case-series 
study using a British health database, that initiation of 
opioid treatment was associated with an increased risk 
of RTCs (IRR 1.70; 99% CI 1.39–2.08).
 Gates et al. [42] found in their study of truck drivers 
involved in fatal RTCs that those who were positive for 
opioid analgesics had higher odds for committing an unsafe 
driving action (OR 1.63, 95% CI 1.12–2.35).
 Assum et al. [4] found no statistically signifi cant 
association between opiate use and RTC involvement 
in a small Norwegian study. Compton and Berning [25] 
reported no signifi cant association between the use of 
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narcotic analgesics and RTC involvement. Romano et al. 
[106] found no signifi cant association between the use of 
narcotic analgesics and fatal crash (crude OR 1.14, 95% 
CI 0.92–1.61). Marquet and coworkers [81] found no 
signifi cant association, but the study was fl awed because 
analysis of alcohol and sedative therapeutic drugs was not 
performed.
 Kuypers and coworkers [66] found an OR for being 
injured of 3.91 (95% CI 0.97–8.68) after analyzing blood 
samples from cases and controls.
 Movig et al. [87] found a positive association between 
opioids and RTCs, although not statistically signifi cant 
(OR 2.35, 95% CI 0.87–6.34). 
 In responsibility studies, Drummer et al. [29] and 
Gadegbeku et al. [41] did not fi nd any signifi cant association 
between opiates and culpability; however, the statistical 
power in those studies was low.
4. Stimulants
a. Amphetamines
 Bernhoft, Hels, and coworkers (Table 2) found in 
the European DRUID case-control studies that the use of 
amphetamines alone was associated with adjusted ORs of 
14.15 (95% CI 5.82–34.42) [12,56,57] for being injured 
and 34.34 (95% CI 13.18–89.49) [12,56] for being killed. 
Blood samples were collected and analyzed from cases and 
oral fl uid or blood samples from controls using equivalent 
cutoff concentrations for blood and oral fl uid. Gjerde et al. 
found in two similar studies in Norway adjusted ORs of 
20.9 (95% CI 7.3–60.0) [48] and 41.6 (95% CI 12.6–137.1) 
[46] after using only amphetamine or methamphetamine, 
while the ORs were 57.1 (95% CI 27.3–119.5) and 76.9 
(95% CI 38.7–152.9) for use of amphetamines in total, 
i.e., with or without other substances. Blood and oral fl uid 
were analyzed with equivalent cutoff concentrations. The 
latest study included practically the same control material 
as used in the Norwegian contribution to the DRUID Project 
and samples from killed drivers for several more years.
 Kuypers et al. [66] published results from the Belgian 
part of the DRUID case-control studies using blood samples 
from cases and controls. For amphetamines (single use) 
the crude OR for being injured in an RTC was 54.82 (95% 
CI 6.09–493.12); an adjusted OR was not calculated.
 Brault et al. [23] found in a Canadian case-control 
study an OR for being killed in an RTC after use of 
amphetamines of 11.0 (95% CI 2.9–41.3) using urine 
samples; this included also amphetamines in combination 
with other substances. Woratanarat et al. [121] found OR 
of 8.88 (95% CI 4.54–17.39), also based on urine samples 
from both cases and controls in Thailand.
 Assum and coworkers [4] found amphetamines in 
blood samples from eight cases and none of the controls 
in a small Norwegian study. In order to calculate the OR, 
0.5 unit was added to negatives and positives among cases 
and controls and 37 negative cases were added to correct 
for sampling bias. The calculated OR for RTC involvement 
was then 29.5 (95% CI 1.5–575.6). The statistical power 
of this study was poor.
 Neither Gadegbeku et al. [41] nor Movig et al. [87] 
found any signifi cant association in a French responsibility 
study and a Dutch case-control study. Gadegbeku and 
coworkers found only 54 drivers positive for amphetamines 
in blood samples in a responsibility study (OR 1.54, 
95% CI 0.66–3.56), which gave a fairly low statistical 
power. Movig and coworkers collected either blood or 
urine from cases and controls; the fraction giving urine 
samples was signifi cantly higher among controls (85%) 
than cases (39%), thereby underestimating the calculated 
ORs because urine samples are positive for drugs for a 
signifi cantly longer time period than blood samples after 
drug use. Another diffi culty was that only 7 out of 110 
cases were positive for amphetamines and 13 out of 816 
controls, giving low statistical power and a wide confi dence 
interval (OR 2.10, 95% CI 0.66–6.73). 
b. Cocaine
 In a Spanish population study using questionnaires, 
Pulido et al. [99] (Table 1) found a signifi cant association 
between weekly cocaine use and involvement in nonfatal 
RTC injury (OR 2.8, 95% CI 1.1–7.1) but not for less 
frequent use. Stoduto et al. [112] found in a similar 
Canadian study a signifi cant association between self-
reported cocaine use last year and involvement in an RTC 
(OR 2.11, 95% CI 1.06–4.18).
 The DRUID case-control studies (Table 2) found no 
signifi cant association between the use of cocaine and 
injuries; the adjusted OR was 1.65 (95% CI 0.66–4.16) 
[12,56,57]. For fatal RTCs the adjusted OR could not be 
calculated; the crude OR was 22.34 (95% CI 3.66–36.53) 
[12,56]. Brault et al. [23] found OR of 4.5 (95% CI 1.2–16.3) 
for the association with fatal RTCs for cocaine alone and 
17.2 (95% CI 10.8–27.2) for all cocaine cases altogether 
based on urine testing. 
 Soderstrom et al. [111] (Table 4) found in an American 
responsibility study signifi cant associations between 
cocaine and RTC injury for male drivers (OR 2.17, 95% 
CI 1.14–4.13); for female drivers a positive association 
was also found, although not statistically signifi cant (OR 
2.34, 95% CI 0.86–6.35).
 Gadegbeku et al. [41] found no signifi cant association 
based on the calculations of only 34 cocaine-positive cases 
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in France (OR 1.17, 95% CI 0.45–3.02). Kuypers et al. [66] 
found only one case and two controls that were positive for 
cocaine and therefore no signifi cant association. Movig et 
al. [87] found 10 cases and 16 controls that were positive 
for cocaine (OR 2.04, 95% CI 0.69–6.09) and thus no 
signifi cant association based on those low numbers when 
using a combination of urine and blood samples.
c. Stimulants in Total Rather Than Specifi ed Substances
 Li et al. [74] and Romano et al. [106] (Table 2) studied 
data recorded in the FARS database and data from the 
American roadside survey of drugs and driving [68]. The 
two studies reported crude OR for stimulants of 3.57 (95% 
CI 2.63–4.76) and 1.87 (95% CI 1.45–2.43), respectively, 
for association with fatal RTCs based on case-control 
calculations without specifying the cutoff concentrations 
used. Analytical fi ndings in urine or blood samples from 
cases and samples of oral fl uid from controls were used 
to calculate the risk. Compton and Berning [25] reported 
no signifi cant association between the use of stimulants 
and RTC involvement in a large study in the US.
 Gates and coworkers [42] (Table 4) used the FARS 
database to study the responsibility in fatal RTCs, and 
found an OR for unsafe driving action of 1.78 (95% 
CI 1.41–2.26) among stimulant-positive truck drivers 
compared to stimulant-negative drivers.
 In Australian responsibility studies, Longo et al. [76] 
found that a higher proportion of drivers who tested positive 
for stimulants in blood were culpable compared to those 
who were drug-free although not statistically signifi cant, 
whereas Drummer et al. [29] found an OR of 2.27 (95% 
CI 0.9–5.6) between stimulant fi ndings and culpability; 
for truck drivers the calculated OR was 8.83 (95% CI 
1.00–78).
5. Antidepressants 
 Bramness and coworkers [22] (Table 1) found a minor 
risk increase for antidepressants (SIR 1.4, 95% CI 1.2–1.6 
for sedating antidepressants and SIR 1.6, 95% CI 1.5–1.7 
for nonsedating antidepressants) in a population study 
using data from prescription and RTC registries.
 Chang and coworkers [24] (Table 3) found an increased 
risk for RTC after one week’s use of antidepressants in 
a Taiwanese registry-based case-control study (OR 1.71, 
95% CI 1.29–2.26). Ravera et al. [101] found signifi cant 
association between the use of SSRIs (OR 2.03, 95% CI 
1.31–3.14) and involvement in RTCs in a similar study.
 Meuleners et al. [84] (Table 4) found in a population-
based case-crossover study greater risk for RTC 
involvement among drivers aged 60 or older (OR 1.8, 
95% CI 1.0–3.3), highest among patients with a chronic 
condition (OR 3.4, 95% CI 1.3–8.5). 
 Orriols et al. [95] used data from the French national 
healthcare insurance database, the national police database, 
and police reports to perform responsibility and case-
crossover studies. They found a signifi cant association 
between the risk of being responsible for an RTC and 
prescription of antidepressants (OR 1.34, 95% CI 1.22–
1.47); the case-crossover analysis showed no association 
with treatment prescription, but the risk of RTCs increased 
after an initiation of antidepressant treatment (OR 1.49, 
95% CI 1.24–1.79) and after a change in antidepressant 
treatment (OR 1.32, 95% CI 1.09–1.60); the exposure was 
considered to start on the day following dispensing.
 In a case-crossover study of elderly drivers, Orriols 
et al. [96] found an increased risk of RTCs in drivers 
with a prescription of antidepressants before their RTC 
when compared with a prescription of antidepressants 
four to eight months before the RTC; OR of 1.19 (95% 
CI 1.08–1.30) to OR of 1.42 (95% CI 1.30–1.55).
 Rapoport et al. [100] found a signifi cant association 
between antidepressant use and RTCs among elderly 
drivers (HR 1.07, 95% CI 1.05–1.10). A prescription 
of a benzodiazepine along with the antidepressant was 
associated with a higher risk (HR 1.23, 95% CI 1.17–1.28), 
whereas the lack of concomitant benzodiazepine yielded 
no increase in RTC risk associated with antidepressant 
use. Similarly, concomitant use of some anticholinergic 
drugs was associated with signifi cantly higher risk.
 Sagberg [107] found a signifi cant risk associated with 
the use of antidepressants in a Norwegian responsibility 
study using questionnaires (OR 1.70, p <0.04). 
 Gibson et al. [44] did not fi nd any elevated risk for 
RTC involvement when using tricyclic antidepressants in 
a case-series study; however, extended use of SSRIs was 
associated with a small increased risk (IRR 1.16, 99% CI 
1.06–1.28). 
 Hou et al. [59] found no signifi cant association in a 
case-control study in Taiwan. Compton and Berning [25] 
reported no signifi cant association in a large case-control 
study in the US. Woratanarat et al. [121] found no signifi cant 
association in a Thai case-control study based on urine 
samples. McGwin et al. [83] found no association between 
antidepressant use and RTC involvement in a study based 
on interviews and RTC registry.
6. Other drugs
 Bramness and coworkers [20] (Table 1) found 
increased RTC risk during the fi rst week after patients 
started using carisoprodol (SIR 3.7, 95% CI 2.9–4.8) when 
linking the Norwegian prescription registry with the RTC 
registry, and no risk increase for salbutamol. In a similar 
study [21], no signifi cant risk increase was observed for 
lithium or valproate, except for young female drivers on 
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lithium (OR 3.2, 95% CI 1.3–6.6). Etminan et al. [36] also 
found an increased risk for RTCs among elderly drivers 
in Canada using lithium (OR 1.80, 95% CI 1.00–3.24).
 In a Canadian case-control study based on analysis 
of biological samples, Brault et al. [23] (Table 2) found 
signifi cant association between any use of PCP (alone or 
in combination) and being killed in an RTC (OR 31.4, 
95% CI 9.2–107.4). 
 Engeland et al. [35] (Table 1) found signifi cant 
association between NSAIDs and RTC involvement (for 
men: OR 1.6, 95% CI 1.2–2.1; for women: OR 1.5 (95% 
CI 1.0–2.0). A signifi cant association was also found 
for penicillins for men: OR 1.4 (95% CI 1.0–2.0); no 
signifi cant association was found for women. No signifi cant 
associations were found for the use of beta-blockers and 
calcium receptor antagonists.
 Hemmelgarn et al. [58] (Table 3) found in a Canadian 
case-control study on antidiabetic drugs based on registry 
data elevated risk for injurious RTC involvement among 
elderly patients using insulin (relative risk (RR) 1.4, 
95% CI 1.0–2.0) and combined use of sulfonylurea and 
metformin (RR 1.3, 95% 1.0–1.7). 
 Rapoport et al. [100] found a signifi cant association 
between the use of antipsychotic drugs and RTC 
involvement among elderly drivers (HR 1.17, 95% CI 
1.07–1.27). The use of proton pump inhibitors or antifungal 
drugs was not associated with RTCs.
 Skurtveit et al. [110] (Table 1) found in a Norwegian 
registry study a signifi cant association between RTCs and 
the use of insulin (SIR 1.4, 95% CI 1.2–1.6); however, 
the association was not statistically signifi cant for drivers 
above 35 years of age.
 A case-control study based on questionnaires published 
by McGwin et al. [83] (Table 3) in the US found signifi cant 
associations between the use of NSAIDs (OR 1.7, 95% 
CI 1.0–2.6), angiotensin-converting enzyme inhibitors 
(OR 1.6, 95% CI 1.0–2.7), or anticoagulants (OR 2.6, 
95% CI 1.0–73) and RTCs among the elderly. The reasons 
for these associations are unclear and might be related to 
the diseases rather than the medication. No signifi cant 
association was found for other hypertension or heart 
medication or for the use of insulin, oral hypoglycemics, 
diuretics, hormones, or arthritis glaucoma medication.
 Oriolls et al. [93] (Table 4) found that drivers exposed 
to prescribed antiepileptic medicines had increased risk of 
being responsible for an RTC (OR 1.74, 95% CI 1.29–2.34); 
the association was also signifi cant for the most severe 
epileptic patients (OR 2.20, 95% CI 1.31–3.69). However, 
case-crossover analysis found no association between 
RTC risk and treatment prescription, suggesting that the 
RTC risk was more likely to be related to the disease with 
seizures than to the effect of antiepileptic medicines.
 Gibson et al. [44] found no effect of receiving a 
prescription for antihistamines on short-term risk for 
RTCs, but extended use was associated with increased risk 
(IRR 1.21; 99% CI 1.04–1.41). They found no signifi cant 
association for the use of beta-blockers.
 Other studies found no signifi cantly increased RTC 
involvement for barbiturates [23,59] and antihistamines 
[97,121] and for elderly patients using warfarin [27], 
carbamazepine [36], or antipsychotics [24].
7. Multiple Drug Use
 The DRUID case-control studies [12,56,57] (Table 2) 
found that the OR associated with multiple drug use was 
larger than for single drug use except for amphetamines. 
Kuypers et al. [66] found an OR of 210.97 (95% CI 
4.90–9088.71) for combination of stimulants and sedatives 
and an OR of 13.70 (95% CI 2.95–63.66) for multiple 
sedatives.
 Assum et al. [4] found an OR for RTC involvement 
of 63.2 (95% CI 3.6–1115.3) after using two drugs and 
29.5 (95% CI 1.5–575.6) when using three drugs.
 Bogstrand et al. [17] found that the OR for being 
injured in an RTC after using two drugs was 13.3 (95% CI 
4.2–41.3) and after using three or more drugs 38.9 (95% 
CI 8.2–185.0). 
 Bogstrand and Gjerde [16] found in a study of drivers 
arrested for drugged driving (both those arrested after 
involvement in an RTC and those arrested for other reasons) 
that multiple drug use was associated with very high risk 
for arrest, particularly the combination of amphetamines 
and benzodiazepines. Arrests for drugged driving based 
on dangerous driving behavior was in this study regarded 
as a proxy for RTC responsibility. 
 Gjerde and coworkers found signifi cantly higher 
OR after using two or more drugs than after using only 
one drug in case-control studies; after using two or more 
medicinal drugs the calculated OR was 17.1 (95% CI 
5.7–51.9) [48] and OR 28.8 (95% CI 7.3–113.6) [46]; 
for two or more illegal drugs the OR was 49.7 (95% 
CI 4.4–561.6) [48]. Highest ORs were found for the 
combination of amphetamines and benzodiazepines: 98.2 
(95% CI 24.9–386.9) [46].
 Mathijssen and Houwing [82] found an OR of 24.0 
(95% CI 11.5–49.7) for being injured in an RTC after 
using combinations of drugs, whereas Movig et al. [87] 
found an OR of 6.05 (95% CI 2.60–14.10) for becoming 
injured. Li et al. found an OR of 3.41 (95% CI 2.43–4.73) 
[74]. 
 However, Woratanarat et al. [121] did not fi nd signifi -
cantly different ORs for multiple and single drug use.
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III. DISCUSSION
 This article is an update of a review by Mørland 
published in 2000 [90]. The present review includes only 
studies published in the English language, primarily in peer-
reviewed journals, from January 1998 to February 2015. 
The results of a large number of investigations have been 
published during this period, and in general the fi ndings 
confi rm the conclusions made in the previous review.
 The European DRUID Project has so far been the 
most comprehensive study of alcohol, drugs, and RTC 
risk. The project included large case-control studies 
[12,56,57,66,101], a responsibility study [41], and other 
epidemiological and experimental studies that are not 
reviewed in this article (for an overview, see project 
deliverables at http://www.druid-project.eu).
 The DRUID Project and other investigations 
documented that alcohol constitutes larger RTC risk 
than the use of any single drug when disregarding the 
concentrations in blood samples of the substances used. 
However, the largest increase in RTC risk has been observed 
for combined use of alcohol and drugs, a combination that 
has not been discussed in this article.
 As mentioned above, a large case-control study was 
performed recently in Virginia Beach, VA [25]. The 
prevalence of drugs was found to be 16.0% among RTC-
involved drivers and 14.4% among matched drivers in 
normal traffi c. The calculated risks for RTC involvement 
in that study was signifi cantly lower for both alcohol and 
drugs than the risks reported in the DRUID Project and 
many other studies. The reasons for this difference may be 
discussed when more study details have been published. 
However, RTC-involved drivers who were too impaired 
to give informed consent were excluded, as well as RTC-
involved drivers below 18 years of age; those two groups 
were regarded as ineligible. Among the eligible drivers, 
5.3% refused to participate. Those three facts might have 
biased the study signifi cantly, producing incorrectly low 
drug prevalence among RTC-involved drivers and thus 
also too low ORs. 
 The prevalence of drugs in fatally injured drivers in 
the US (28.3% in 2010) [18] was signifi cantly higher than 
that reported in the Virginia Beach study (16.0%). This 
could be related to the inclusion of all types of RTCs, 
even quite trivial ones, in the study [25], in addition to 
the factors mentioned above. 
A. Benzodiazepines and z-Hypnotics
 A total of 28 different analytical epidemiological 
studies dealt with effects of benzodiazepines and/or 
z-hypnotics or sedatives in general. In 25 of these studies 
there was a statistically signifi cant association between 
benzodiazepines/z-hypnotics (or use of unspecified 
sedatives) and RTCs. Three studies did not report a 
signifi cant association, but two of these had low statistical 
power and one found a weak but not statistically signifi cant 
association. Thus in sum, analytical epidemiological studies 
published since 1998 in general found a clear association 
between use of benzodiazepines and/or z-hypnotics and 
increased RTC risk.
B. Cannabis
 A total of 36 different analytical epidemiological 
studies have presented data for the effects of cannabis, 
and 23 found a statistically signifi cant association between 
cannabis use and RTCs and injuries. The calculated OR was 
typically in the range 1–4, and was thus similar to the risk 
observed after starting therapeutic use of a benzodiazepine. 
Thirteen studies did not report signifi cant associations, 
but seven of these had either low statistical power or 
questionable study design. Signifi cant associations as 
well as lack of signifi cant associations were reported in 
all three types of study design, i.e., in cohort, case-control, 
and responsibility/case-crossover. 
C. Opioids
 A total of 25 different analytical epidemiological 
studies dealing with the effects of opioids were identifi ed. 
In 17 of these studies a statistically signifi cant association 
between opioid use and RTCs was found; in eight studies 
the association was not statistically signifi cant. However, 
seven of those studies had either low statistical power and/
or questionable design. Signifi cant as well as nonsignifi cant 
associations were found in case-control and responsibility/
case-crossover studies. The three cohort studies performed 
found signifi cant associations between prescribed opioids 
(with the exception of tramadol) and RTC risk. Thus in 
sum, analytical epidemiological studies performed after 
1998 found in most cases an association between opioid 
use and RTCs.
D. Stimulants
1. Amphetamines
 Ten different analytical epidemiological studies 
have included amphetamines: seven case-control studies 
and three responsibility studies. Eight of these found 
statistically signifi cant associations between amphetamine 
use and RTC risk. The two studies that reported no 
signifi cant associations still reported a trend. One of these 
studies most probably underestimated the calculated risk 
108
Forensic Science Review (www.forensicsciencereview.com)   •   Volume Twenty-Seven  Number Two  •  July 2015
due to different distribution of blood and urine samples 
among control and cases. The median OR for RTC 
involvement in the 10 studies was 18. Thus in sum, the 
epidemiological studies performed since 1998 report a clear 
association between amphetamine use and increased RTC 
risk. Several of these studies found that amphetamine and 
methamphetamine were associated with higher RTC risk 
than any other drug, also when not combined with other 
psychoactive substances.
 High concentrations of amphetamines may have 
harmful effects on self-perception, critical judgment, 
and risk taking, whereas when the stimulating effects are 
disappearing, a period associated with fatigue, anxiety, 
and irritability may occur even if the drug is still present 
in the body. The risk for involvement in RTCs might be 
increased both during the stimulated and fatigue periods 
when taking high doses [75]. It is likely that problematic 
amphetamine users and addicts constitute a larger traffi c 
safety problem than drivers that occasionally are taking 
small doses of amphetamines to stay awake and alert 
during long journeys with little time for resting.
2. Cocaine 
 Nine different analytical epidemiological investigations 
studied the effect of cocaine. Five found an association 
between cocaine use and crashes, whereas 4 studies 
did not conclude with a signifi cant association. Three 
of the latter had, however, low statistical power. The 
ORs reported in all studies were in general lower than 
those reported for amphetamines. Six of the studies 
included both amphetamines and cocaine. In all of these, 
regardless of whether an association between stimulant 
use and accidents was found or not, the OR-values were 
always higher for amphetamines. Thus in sum analytical 
epidemiological studies performed since 1998 found in 
most cases an association between cocaine use and crash 
risk. This association appeared, however, to be somewhat 
weaker than for amphetamines. 
E. Antidepressants
 Thirteen different analytical epidemiological studies 
dealing with the effects of antidepressants were identifi ed. 
In eight of these there was a statistical signifi cant 
association between use of antidepressants and RTCs; 
one additional study reported a small risk increase for 
SSRIs, but not for tricyclic antidepressants. No signifi cant 
association was observed in four studies. Signifi cant 
as well as nonsignifi cant associations were found in 
case-control and responsibility/case-crossover studies. 
The only cohort study performed found a statistically 
signifi cant association. One crossover study indicated 
that the condition itself (depression) was associated with 
increased risk, but also that the initial period after start of 
drug treatment represented a similar association. In sum, 
the analytical epidemiological studies published since 1998 
indicate that there is some association between the use of 
antidepressants, both tricyclic and SSRIs, and increased 
RTC risk. The calculated statistically signifi cant ORs were, 
however, around two or lower.
F. Other Drugs
 In general there were few studies on the associations 
between other drugs and RTCs. Antihistamines were 
studied in three reports; two of them did not fi nd an 
association with RTCs, while the third one found a modest 
increased risk. The most marked risk increase (OR 31.4) 
was found for the association between RTCs and any use 
of PCP, and the risk increase after using carisoprodol (SIR 
3.8) was higher than for many benzodiazepines.
G. Multiple Drug Use
 Twelve different analytical epidemiological studies 
published since 1998 all found that drug combinations 
increased the ORs for the association with RTCs compared 
to single drug use. In some studies the calculated increases 
in OR were very marked.
CONCLUSIONS
 Approximately 15 analytical epidemiological studies 
published as of 1998 were included in the review published 
in 2000. In the present paper we have identifi ed 72 
analytical epidemiological studies published after those 
included in the former review. The scientifi c basis has thus 
increased substantially within this fi eld of research, and 
thus constitutes a broader background for the following 
conclusions.
 Epidemiological studies have found that after alcohol, 
amphetamines are the single substances with highest risk 
for RTC involvement. Increased RTC risk has also been 
well documented for cocaine, cannabis, benzodiazepines, 
z-hypnotics, opioids, and for some antidepressants. 
Increased RTC risk has also been found for carisoprodol 
and PCP, although few epidemiological studies have been 
performed on those substances. Associations with RTCs 
have been found for some other drugs as well, but it is 
unclear whether this association was more dependent on 
the underlying disease than the drug use per se.
 The combination of two or more psychoactive drugs 
has been found to be more risky than single use. However, 
the combination of psychoactive drugs with alcohol is 
associated with the highest RTC risk.
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 The calculated risks for involvement in RTCs 
associated with the use of different drugs, particularly 
nontherapeutic use, are closely related to behavioral 
factors such as risk-taking behavior and impulsivity. The 
attitudes toward driving after drug use may also vary 
between countries and between groups within countries. 
Therefore, the calculated risks associated with drug use may 
vary between different studies. In addition, abuse of drugs 
for longer periods can cause somatic and mental changes 
that may increase the RTC risk as well. Therapeutic drug 
use may also constitute a lower risk for RTC involvement 
than nontreated illness. For those reasons it is diffi cult to 
determine quantitatively the risk posed by the use of a 
single drug dose per se in epidemiological studies. The 
risk depends on who is taking the drug, why, when, how 
much, how often, and under which circumstances.
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